A pilot trial of belimumab for atherosclerosis associated autoimmunity in COPD patients

Conclusion: Treatment with belimumab in COPD is safe and reduces anti-GRP78 levels, an autoantibody linked with CVD in this population.

Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Mkorombindo, T., Wade, R. C., Yuan, K., Robison, S. W., Christenson, A. E., Wells, J. M., Dransfield, M. T., Duncan, S. R. Tags: 05.03 - Allergy and immunology Source Type: research